Details
Description
In this report we examined total available follow-up time of patients exposed to guselkumab, risankizumab, or tildrakizumab in the Sentinel Distributed Database (SDD). This is the first report of an ongoing plan to monitor uptake of these drugs until sufficient follow-up time accrues among treated patients to conduct a 1:1 propensity-score-matched analysis for non-Hodgkin lymphoma (NHL) in this cohort. We distributed this request to 16 Sentinel Data Partners on July 6, 2020. The study period included data from July 13, 2017 through December 31, 2019.